Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018

Abstract

BackgroundA novel meningococcal serogroup A conjugate vaccine (MACV [MenAfriVac]) was developed as part of efforts to prevent frequent meningitis outbreaks in the African meningitis belt. The MACV was first used widely and with great success, beginning in December 2010, during initial deployment in Burkina Faso, Mali, and Niger. Since then, MACV rollout has continued in other countries in the meningitis belt through mass preventive campaigns and, more recently, introduction into routine childhood immunization programs associated with extended catch-up vaccinations.MethodsWe reviewed country reports on MACV campaigns and routine immunization data reported to the World Health Organization (WHO) Regional Office for Africa from 2010 to 2018, as well as country plans for MACV introduction into routine immunization programs.ResultsBy the end of 2018, 304 894 726 persons in 22 of 26 meningitis belt countries had received MACV through mass preventive campaigns targeting individuals aged 1–29 years. Eight of these countries have introduced MACV into their national routine immunization programs, including 7 with catch-up vaccinations for birth cohorts born after the initial rollout. The Central African Republic introduced MACV into its routine immunization program immediately after the mass 1- to 29-year-old vaccinations in 2017 so no catch-up was needed.ConclusionsFrom 2010 to 2018, successful rollout of MACV has been recorded in 22 countries through mass preventive campaigns followed by introduction into routine immunization programs in 8 of these countries. Efforts continue to complete MACV introduction in the remaining meningitis belt countries to ensure long-term herd protection.

Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefit–risk analysis of health benefits versus excess risk of SARS-CoV-2 infection

“…The target age for N meningitidis serogroup A routine immunisation varies by country and is given along with the first or second dose of measles vaccine; it is given at 9 months in Central African Republic, Chad, Côte d'Ivoire, Mali, Niger, and Sudan, at 15 months in Burkina Faso, and at 18 months in Ghana. 16 We did not consider BCG or hepatitis B birth dose because they are recommended for administration shortly after birth and thus were assumed not to require an additional vaccination visit, even though home births or delayed administration might be common in some parts of Africa.…”

A meta-analytic evaluation of sex differences in meningococcal disease incidence rates in 10 countries

“…Serogroups A, B, C, W and Y are responsible for most cases of invasive disease. In the 'meningitis belt' in Africa, immunisation against group A meningococcus was introduced in 2010 [3] and some countries in Europe routinely immunise infants against group C meningococcus using the conjugate vaccine [4]. Serogroup B is now the commonest strain across Europe (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/ attachment_data/file/842368/hpr3819_IMD-ann.pdf) and only recently has an effective vaccine become available [5].…”

Eliminating Meningococcal Epidemics From the African Meningitis Belt: The Case for Advanced Prevention and Control Using Next-Generation Meningococcal Conjugate Vaccines

“…The second includes a group of countries with historically lower rates of meningococcal disease that are adjacent to hyperendemic countries and have areas of high epidemic risk and occasional meningitis epidemics on their shared borders. Benin, Burundi, the Central African Republic, Côte d’Ivoire, the Democratic Republic of the Congo, Eritrea, Guinea, Guinea-Bissau, Kenya, Mauritania, Rwanda, Senegal, South Sudan, Tanzania, and Uganda fall into this second category [6, 13].…”

“…Over the next 8 years, >300 million Africans were immunized, and serogroup A meningococcal infections virtually disappeared wherever the vaccine was given. Starting in 2016, meningitis belt countries began introducing MACV the serogroup A conjugate vaccine into their routine immunization programs [5, 6].…”